These webinars are organised by the APSAD Smoking and Vaping Cessation Professionals (ASVCP) Special Interest Group for APSAD members, providing the opportunity to share information and knowledge through regular contact and webinars. The aim is the promotion of optimal smoking cessation practice in Australasia by trained health professionals incorporating evidence-based practice with an ongoing learning objective.
Membership of the ASVCP-SIG is open to APSAD members with an interest in Smoking and Vaping Cessation. For information contact Membership Services at This email address is being protected from spambots. You need JavaScript enabled to view it..
Coming Up in the ASVCP Webinar Series
March Webinar
Information coming soon.
You can watch the 2025 webinar series collection here.
Individual webinars are available below and go back to 2018.
|
Registration Terms and Conditions Any persons affiliated with tobacco entities (current, in the past, or have future plans), tobacco lobbyists, either professionally or on a personal basis, will be ineligible to attend or present at any APSAD webinar or event. APSAD’s policy is aligned with the World Health Organization’s Framework Convention on Tobacco Control, Article 5.3: There is a fundamental and irreconcilable conflict between the tobacco industry’s interest and public health policy interests. Registrations from such persons will be cancelled without notice. Paid registrations of such persons will not be refunded. |
|
Disclaimer The views expressed by presenters and speakers are not necessarily the views of APSAD, and the Society does not accept responsibility for any information, research, recommendation or advice presented. |
-----------------------------------------------------------------------------------------------
Watch ASVCP Webinars
Previous Recordings
February 2026 l Cytisine: The Comeback Compound in Cessation
This presentation explores cytisine, a long‑standing plant‑derived partial agonist of the nicotinic acetylcholine receptor that is experiencing renewed global interest as a cessation aid. The session begins with a brief historical overview, tracing cytisine’s origins from Eastern European use in the 1960s through to its modern resurgence as an affordable, evidence‑based pharmacotherapy. It then summarises the clinical evidence demonstrating cytisine’s effectiveness for smoking cessation, including large, randomised trials showing superiority to placebo and comparability or superiority to varenicline. Emerging findings on its potential role in vaping cessation are also discussed.
The presentation concludes with a practical focus on clinical application, covering dosing regimens, side‑effect profiles, patient suitability, and how cytisine can be integrated into routine tobacco dependence treatment pathways.
Presenter: Professor Hayden McRobbie, Professor of Population Health, Wolfson Institute of Public Health, Queen Mary University of London
January 2026 l Break the Habit Study (Vaping vs varenicline for smoking cessation among people experiencing social disadvantage: a consumer guided clinical trial)
Presenter: Saumya Bhatta, Clinical Trials Coordinator for the Tobbaco Research Group, NDARC, UNSW Sydney
September 2025 l Varenicline: It's better than you think
We'll ask these questions.
- Does Varenicline really work?
- How might it work?
- Does it interact with other drugs?
- Some clients say it causes them neuropsychiatric symptoms. Is this true?
- What about people with mental illness?
- What about people that are alcohol dependent?
- Dosing and administration, what's best practice?
- Any populations that should not be using it?
- Common side-effects and any simple steps to reduce them?
And...What the journal articles and text books won’t tell you
Presenter: James McLennan, State-Wide Training Coordinator - smoking and vaping cessation from Alcohol and Drug Service, St Vincent's Hospital Sydney
August 2025 l Information & Update Session: Credentialling process for Nicotine Treatment Specialists
This webinar will be a general information and update session on the credentialling process for Nicotine Treatment Specialists. This is a great opportunity to ask any questions and find out more about becoming a Nicotine Treatment Specialist!
Presenter: Professor Ryan Courtney, Program Lead Tobacco Research Group, National Drug & Alcohol Research Centre, University of New South Wales, Sydney; Associate Professor/ National Heart Foundation Future Leader Fellow; and ASVCP Chair
June 2025 l Smoking and Vaping Cessation in the Youth Custody Setting NSW
There are high rates of all smoking behaviours in young people entering youth custody. This presentation will provide recent data on rates of all smoking behaviours in young people on admission, and approaches to managing nicotine dependence in the smoke-free environment of youth justice.
Presenters:
Dr Leigh Haysom, Clinical Director Adolescent Health, Adolescent Health, Justice Health and Forensic Mental Health Network
Anna Barker, Staying Quit Senior Project Officer, Population and Preventive Health, Justice Health and Forensic Mental Health Network
May 2025 l Leveraging the new National Lung Cancer Screening Program for Smoking Cessation: Implications and Implementation
Australia’s National Lung Cancer Screening Program starts in July, for people with smoking history and at high risk of lung cancer but without any symptoms. In this webinar, A/Prof Marshall will provide an overview of the National Program and discuss opportunities to integrate smoking cessation into screening discussions. Dr White will examine the program’s implications for cessation services, with a particular focus on the role of Quitline in supporting individuals identified through screening. Webinar attendees will gain insights into best practices for leveraging lung cancer screening as a key moment for engaging smokers in evidence-based cessation support.
Presenters: Associate Professor Henry Marshall & Dr Kahren White
April 2025 l Smoking cessation and vaping cessation in New Zealand : Two community-based pragmatic trials to inform practice and policy.
Reduced harm e-cigarettes are endorsed by the Aotearoa New Zealand government as an effective smoking cessation treatment. Once people have fully switched to vaping, it's recommended that they then stop vaping (provided there is no risk of relapse back to smoking). This webinar will first present the results of 1 a large, pragmatic community-based trial undertaken in Aotearoa New Zealand, exploring the effectiveness of combining cytisine with nicotine e-cigarettes to quit smoking, compared to single product use. The rationale and design of a large, pragmatic community-based vaping cessation trial (currently underway in Aotearoa New Zealand) will also be discussed.
Presenters: Professor Natalie Walker, and Professor Chris Bullen.
March 2025 l Tackling Tobacco: Approaching 20 years of partnership with the community service sector
As the Tackling Tobacco program approaches its 20th year of implementation in NSW, this webinar will provide an overview of the program, including key milestones, contributions to the evidence base and the evolution of the program over time. The effectiveness of the program will be examined through the results of randomised controlled trials and case studies, with a focus on the impact the program has had in non-government alcohol and other drug services. Real-world examples of the program’s impact will be showcased, illustrating the practical applications of the implementation strategies and lessons learned from extensive program delivery across almost two decades.
Presenter: Laura Twyman, Program Lead, Tobacco Cessation, Tobacco Control Unit, Cancer Prevention and Advocacy Division, Cancer Council NSW
February 2025 l Interim evaluation of the Incentive to Quit (I2Q) pilot program for smoking and vaping cessation
The Incentive to Quit (I2Q) Pilot Program is a government-funded initiative aimed at reducing smoking and vaping rates among high-prevalence nicotine users in South Australia. Implemented across four health service groups in the Northern Adelaide Local Health Network (NALHN), the program offered financial incentives of up to $150 to encourage quit attempts and engagement with Quitline services.
This presentation will describe key findings such as participant reach; 3- and 6-month cessation rates and Quitline engagement for those who have completed this milestone; cost-effectiveness; implementation barriers and enablers; participant feedback; policy implications; and next steps.
Presenter: Kelsey Sharrad, PhD Candidate, School of Medicine, University of Adelaide; Research Coordinator, Department of Sleep and Respiratory Medicine, Women's and Children's Hospital; Senior Project Manager, Houd Research Group
- Prev
- Next >>